IL212651A - Preparations for the treatment of acute lymphoblastic leukemia in children - Google Patents

Preparations for the treatment of acute lymphoblastic leukemia in children

Info

Publication number
IL212651A
IL212651A IL212651A IL21265111A IL212651A IL 212651 A IL212651 A IL 212651A IL 212651 A IL212651 A IL 212651A IL 21265111 A IL21265111 A IL 21265111A IL 212651 A IL212651 A IL 212651A
Authority
IL
Israel
Prior art keywords
compositions
treatment
lymphoblastic leukemia
acute lymphoblastic
pediatric acute
Prior art date
Application number
IL212651A
Other languages
English (en)
Hebrew (he)
Other versions
IL212651A0 (en
Original Assignee
Amgen Res Munich Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Res Munich Gmbh filed Critical Amgen Res Munich Gmbh
Publication of IL212651A0 publication Critical patent/IL212651A0/en
Publication of IL212651A publication Critical patent/IL212651A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
IL212651A 2008-11-07 2011-05-03 Preparations for the treatment of acute lymphoblastic leukemia in children IL212651A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11232308P 2008-11-07 2008-11-07
US18329109P 2009-06-02 2009-06-02
US22126909P 2009-06-29 2009-06-29
PCT/EP2009/007969 WO2010052013A1 (en) 2008-11-07 2009-11-06 Treatment of pediatric acute lymphoblastic leukemia

Publications (2)

Publication Number Publication Date
IL212651A0 IL212651A0 (en) 2011-07-31
IL212651A true IL212651A (en) 2015-03-31

Family

ID=41796119

Family Applications (1)

Application Number Title Priority Date Filing Date
IL212651A IL212651A (en) 2008-11-07 2011-05-03 Preparations for the treatment of acute lymphoblastic leukemia in children

Country Status (27)

Country Link
US (2) US20110262440A1 (https=)
EP (4) EP2918604B1 (https=)
JP (2) JP5798036B2 (https=)
KR (1) KR101695329B1 (https=)
CN (2) CN102209729B (https=)
AU (1) AU2009313039B2 (https=)
BR (1) BRPI0921341A2 (https=)
CA (1) CA2742242C (https=)
CY (3) CY1116160T1 (https=)
DK (3) DK3330293T3 (https=)
ES (3) ES2748126T3 (https=)
HK (1) HK1255590B (https=)
HR (3) HRP20150400T1 (https=)
HU (3) HUE036922T2 (https=)
IL (1) IL212651A (https=)
LT (2) LT2918604T (https=)
MX (1) MX2011002931A (https=)
NO (1) NO2918604T3 (https=)
NZ (1) NZ591312A (https=)
PL (3) PL2918604T3 (https=)
PT (3) PT2344539E (https=)
RS (3) RS59348B1 (https=)
RU (3) RU2536933C2 (https=)
SG (1) SG195549A1 (https=)
SI (3) SI2918604T1 (https=)
SM (3) SMT201900546T1 (https=)
WO (1) WO2010052013A1 (https=)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6358588A (ja) * 1986-08-29 1988-03-14 Toshiba Corp バ−コ−ド読取装置
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
PL2918604T3 (pl) * 2008-11-07 2018-05-30 Amgen Research (Munich) Gmbh Leczenie pediatrycznej ostrej białaczki limfoblastycznej
US20120039943A1 (en) * 2009-01-09 2012-02-16 Oxford Biomedica (Uk) Limited Factors
US20150231241A1 (en) * 2012-08-14 2015-08-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JP6499079B2 (ja) * 2012-11-13 2019-04-10 バイオエヌテック アーゲーＢｉｏＮＴｅｃｈ ＡＧ クローディンを発現するガン疾患を処置するための剤
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
CN103131777A (zh) * 2013-02-05 2013-06-05 南京艾迪康医学检验所有限公司 用于检测e2a-pbx融合基因相对表达量的试剂盒
DK3105252T3 (da) 2014-02-12 2019-10-14 Michael Uhlin Bispecifikke antistoffer til anvendelse ved stamcelletransplantation
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
SI3149480T1 (sl) 2014-05-30 2019-05-31 Amgen Research (Munich) Gmbh Stratifikacija tveganj pri bolnikih z akutno limfoblastno levkemijo prekurzorjev b
US20170252364A1 (en) 2014-07-30 2017-09-07 Mor Research Applications Ltd. Compositions for treatment of acute lymphoblastic leukemia and methods of use thereof
WO2016061368A1 (en) * 2014-10-15 2016-04-21 The Children's Hospital Of Philadelphia Compositions and methods for treating b-lymphoid malignancies
KR102614189B1 (ko) 2014-11-17 2023-12-18 리제너론 파아마슈티컬스, 인크. Cd3xcd20 이특이적 항체를 이용한 종양의 치료 방법
CN107635578A (zh) 2015-02-05 2018-01-26 Stc.Unm 公司 抗前‑bcr拮抗剂和方法
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
JP6961490B2 (ja) 2015-04-08 2021-11-05 ノバルティス アーゲー Ｃｄ２０療法、ｃｄ２２療法、およびｃｄ１９キメラ抗原受容体（ｃａｒ）発現細胞との併用療法
AU2016263464B2 (en) * 2015-05-20 2021-12-23 Amgen Research (Munich) Gmbh B-cell depletion as a diagnostic marker
AU2016325630B2 (en) 2015-09-23 2022-11-17 Regeneron Pharmaceuticals, Inc. Optimized anti-CD3 bispecific antibodies and uses thereof
AU2016378573A1 (en) * 2015-12-22 2018-07-19 Regeneron Pharmaceuticals, Inc. Bispecific anti-CD20/anti-CD3 antibodies to treat acute lymphoblastic leukemia
GB201602974D0 (en) * 2016-02-19 2016-04-06 Clube Jasper R Engineered cells & methods (1)
CA3017743A1 (en) * 2016-03-14 2017-09-21 Millennium Pharmaceuticals, Inc. Method of preventing graft versus host disease
CA3024725A1 (en) * 2016-06-06 2017-12-14 Juno Therapeutics, Inc. Methods for the treatment of b cell malignancies using adoptive cell therapy
CA3045339A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
UY37726A (es) * 2017-05-05 2018-11-30 Amgen Inc Composición farmacéutica que comprende constructos de anticuerpos biespecíficos para almacenamiento y administración mejorados
AU2018275894B2 (en) 2017-06-02 2025-04-24 Juno Therapeutics, Inc. Articles of manufacture and methods for treatment using adoptive cell therapy
WO2019089858A2 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Methods of assessing or monitoring a response to a cell therapy
KR102083481B1 (ko) 2018-03-22 2020-03-02 강원대학교산학협력단 아연-키토산 나노 입자를 포함한 급성 림프구성 백혈병 치료용 약학조성물
CA3110513A1 (en) 2018-08-31 2020-03-05 Regeneron Pharmaceuticals, Inc. Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
JP7680358B2 (ja) * 2019-01-30 2025-05-20 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー 癌抗原を標的とするｄｎａコード化二重特異性ｔ細胞エンゲージャーおよび癌治療薬における使用方法
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
JP7489407B2 (ja) 2019-05-21 2024-05-23 ノバルティス アーゲー Ｃｄ１９結合分子及びその使用
JP6881658B2 (ja) 2019-07-05 2021-06-02 小野薬品工業株式会社 Ｐｄ−１／ｃｄ３二重特異性タンパク質による血液がん治療
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
EP4294837A1 (en) 2021-02-16 2023-12-27 Children's Health Care d/b/a Children's Minnesota Methods for treating b-all by administering a pre-bcr complex antagonist
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
EP4415829A1 (en) 2021-10-15 2024-08-21 Amgen Research (Munich) GmbH Subcutaneous administration of cd19-binding t cell engaging antibodies
WO2025101672A1 (en) 2023-11-06 2025-05-15 City Of Hope Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法
WO2025250648A1 (en) * 2024-05-28 2025-12-04 Ohio State Innovation Foundation Methods and compositions comprising tagless blinatumomab
WO2026072671A1 (en) 2024-09-24 2026-04-02 City Of Hope Methods comprising oncolytic viruses expressing bcmat and bcma-targeted therapies

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4119397A (en) * 1996-08-28 1998-03-19 Viva Diagnostika Diagnostische Produkte Gmbh Novel combination preparations and their use in immunodiagnosis and immunotherapy
US7112324B1 (en) * 1998-04-21 2006-09-26 Micromet Ag CD 19×CD3 specific polypeptides and uses thereof
JP2008501621A (ja) * 2003-05-31 2008-01-24 マイクロメット アクツィエン ゲゼルシャフト Ｂ細胞関連疾患を処置するための二重特異性抗ｃｄ３、抗ｃｄ１９抗体構築物を含む薬学的組成物
MXPA06004035A (es) * 2003-10-16 2006-08-31 Micromet Ag Aglutinantes cd3 de-inmunizados multi-especificos.
HRP20150175T1 (en) 2005-12-16 2015-03-27 Amgen Research (Munich) Gmbh Means and methods for the treatment of tumorous diseases
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
DK2352763T4 (da) * 2008-10-01 2022-10-17 Amgen Res Munich Gmbh Bispecifikke enkeltkædede antistoffer med specificitet for højmolekylære målantigener
PL2918604T3 (pl) * 2008-11-07 2018-05-30 Amgen Research (Munich) Gmbh Leczenie pediatrycznej ostrej białaczki limfoblastycznej
CA2747835A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010083442A1 (en) * 2009-01-19 2010-07-22 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CA2763633A1 (en) * 2009-05-27 2010-12-02 Gary T. Wang Pyrimidine inhibitors of kinase activity
BR112012006252A2 (pt) * 2009-09-20 2017-05-23 Abbott Lab "formas cristalinas de abt-263 e solvatos para o uso no tratamento de doenças relacionadas á proteína bcl-2".
RS54655B2 (sr) * 2009-10-27 2021-04-29 Amgen Res Munich Gmbh Dozni režim za primenu cd19xcd3 bispecifičnog antitela

Also Published As

Publication number Publication date
RU2011122827A (ru) 2012-12-20
EP2344539A1 (en) 2011-07-20
EP2344539B1 (en) 2015-02-11
LT3330293T (lt) 2019-10-10
CN102209729B (zh) 2016-05-25
PT2344539E (pt) 2015-04-01
KR20110091669A (ko) 2011-08-12
AU2009313039B2 (en) 2015-06-18
JP6130451B2 (ja) 2017-05-17
CN102209729A (zh) 2011-10-05
EP2918604B1 (en) 2017-12-20
ES2535257T3 (es) 2015-05-07
US20110262440A1 (en) 2011-10-27
NO2918604T3 (https=) 2018-05-19
DK2918604T3 (en) 2018-03-19
DK2344539T3 (en) 2015-05-04
SI2918604T1 (en) 2018-04-30
RS56989B1 (sr) 2018-05-31
EP2918604A1 (en) 2015-09-16
HUE025452T2 (en) 2016-05-30
PL2344539T3 (pl) 2015-07-31
RU2677324C2 (ru) 2019-01-16
HUE046222T2 (hu) 2020-02-28
PT3330293T (pt) 2019-10-18
EP3330293A1 (en) 2018-06-06
JP5798036B2 (ja) 2015-10-21
US20230235053A1 (en) 2023-07-27
CY1122428T1 (el) 2021-01-27
CN106390114A (zh) 2017-02-15
SI3330293T1 (sl) 2019-10-30
RS53980B1 (sr) 2015-10-30
AU2009313039A1 (en) 2010-05-14
JP2012508163A (ja) 2012-04-05
EP3330293B1 (en) 2019-07-24
HK1255590B (en) 2020-07-10
CY1120022T1 (el) 2018-12-12
KR101695329B1 (ko) 2017-01-23
HRP20191715T1 (hr) 2019-12-13
HRP20180426T1 (hr) 2018-04-20
HRP20150400T1 (hr) 2015-05-08
SMT201500104B (it) 2015-07-09
CA2742242C (en) 2023-01-10
RS59348B1 (sr) 2019-10-31
PT2918604T (pt) 2018-03-02
SMT201900546T1 (it) 2019-11-13
ES2748126T3 (es) 2020-03-13
CY1116160T1 (el) 2017-02-08
SG195549A1 (en) 2013-12-30
ES2662929T3 (es) 2018-04-10
NZ591312A (en) 2012-09-28
HK1215258A1 (en) 2016-08-19
RU2014141180A3 (https=) 2018-06-09
EP3594237A1 (en) 2020-01-15
MX2011002931A (es) 2011-04-11
RU2536933C2 (ru) 2014-12-27
WO2010052013A1 (en) 2010-05-14
LT2918604T (lt) 2018-03-26
HK1158667A1 (en) 2012-07-20
RU2014141180A (ru) 2016-05-10
RU2736802C2 (ru) 2020-11-20
SMT201800149T1 (it) 2018-05-02
JP2015232023A (ja) 2015-12-24
RU2018144313A3 (https=) 2020-06-15
BRPI0921341A2 (pt) 2016-04-26
HUE036922T2 (hu) 2018-08-28
DK3330293T3 (da) 2019-10-07
PL2918604T3 (pl) 2018-05-30
IL212651A0 (en) 2011-07-31
PL3330293T3 (pl) 2020-02-28
CA2742242A1 (en) 2010-05-14
SI2344539T1 (sl) 2015-06-30
RU2018144313A (ru) 2020-06-15

Similar Documents

Publication Publication Date Title
IL212651A (en) Preparations for the treatment of acute lymphoblastic leukemia in children
AU2018260815A1 (en) Treatment of Acute Lymphoblastic Leukemia
IL248204A0 (en) Combined treatment of tumors expressing 38cd
PL2340042T3 (pl) Sposoby i kompozycje do leczenia raka
ZA201001264B (en) 1-amino-alkylcycohxane derivatives for the treatment of cochleat tinnitus
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
PL2209458T3 (pl) Kompozycje do traktowania skóry
GB0909297D0 (en) Composition for the treatment of skin conditions
IL210290A0 (en) Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
BRPI0914139A2 (pt) composições pediátricas para o tratamento de esclerose múltipla
PL2331092T3 (pl) Sposoby i kompozycje do podawania 3-halopirogronianiu i związków pochodnych w leczeniu nowotworu
EP2174956A4 (en) COMPOSITIONS FOR ANTIFIBRINOLYSIS THERAPY
IL208624A0 (en) Compositions for the treatment of lice
PL2252302T3 (pl) Kompozycja do leczenia zapalenia kości i stawów
GB0723100D0 (en) Treatment of HFnEF
GB0808326D0 (en) Compositions and methods for the treatment of fybromyalgia
IL184620A0 (en) Composition for the treatment of inflammation
GB0602857D0 (en) The treatment of sialorrhoea
GB0809319D0 (en) The treatment of puritus
GB0602855D0 (en) The Treatment Of Sialorrhoea
GB0602858D0 (en) The treatment of sialorrhoea
GB0719613D0 (en) The treatment of pruritis
GB0705674D0 (en) Composition for the treatment of halitosis
IL210519A0 (en) Anti-phthiraptera treatment compositions

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed